PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Infectious Diseases, The First Hospital of Changsha, Changsha, China.\', \'Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.\', \'Department of Respiratory Medicine, The First Hospital of Changsha, Changsha, China.\', \'National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.\', \'Department of Intensive Care Unit, The First Hospital of Changsha, Changsha, China.\', \'Department of Pediatrics, The First Hospital of Changsha, Changsha, China.\', \'Department of Internal Medicine, The First Hospital of Changsha, Changsha, China.\', \'Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.\', \'Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China. Electronic address: jiangyongfang@csu.edu.cn.\', \'Department of Infectious Diseases, The First Hospital of Changsha, Changsha, China. Electronic address: 1286779459@qq.com.\', \'National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China. Electronic address: tanwj@ivdc.chinacdc.cn.\', \'Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China. Electronic address: gongguozhong@csu.edu.cn.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S1201-9712(20)30597-X10.1016/j.ijid.2020.07.053
?:hasPublicationType
?:journal
  • International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
is ?:pmid of
?:pmid
?:pmid
  • 32758689
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32758689>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32758689>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all